Clinical and Molecular Features in IDH-Mutant Astrocytomas and IDH-Wild-Type Glioblastomas With and Without MMR Gene Mutations in the Primary Tumor
| Subgroup . | n . | Gender (M:F) . | Age (Years) . | 2021 WHO Grade (2:3:4) . | CDKN2A (Homozygous Deletion:Retained)* . | MGMT Promoter (Methylated: Unmethylated)* . | Tumor Mutation Burden (Mutations/Mb) . | CNV (%) . | Median PFS (Months) . | Median OS (Months) . |
|---|---|---|---|---|---|---|---|---|---|---|
| IDH-mutant astrocytoma | ||||||||||
| MMR-mutant | 18 | 10:8 | 35.1 ± 2.9 | 1:3:14 | 9:8 | 8:6 | 84.9 ± 13.0 | 21.3 ± 3.2 | 62.1 | 78.5 |
| MMR-wild type | 361 | 234:127 | 35.2 ± 0.5 | 155:118:88 | 67:294 | 93:60 | 15.1 ± 0.9 | 17.3 ± 0.7 | 97.8 | 161.0 |
| P-value | - | =0.4548 | =0.9658 | <0.0001 | =0.0021 | =0.7829 | <0.0001 | =0.1381 | =0.0528 | =0.0069 |
| IDH-wild-type glioblastoma | ||||||||||
| MMR-mutant | 20 | 9:11 | 51.7 ± 3.0 | 0:0:20 | 9:11 | 9:8 | 131.9 ± 14.8 | 20.6 ± 2.7 | 6.0 | 27.2 |
| MMR-wild type | 906 | 554:352 | 54.9 ± 0.5 | 0:0:906 | 256:261 | 158:343 | 13.6 ± 0.6 | 18.8 ± 0.3 | 10.0 | 22.0 |
| P-value | - | =0.1670 | =0.3707 | - | =0.8207 | =0.0702 | <0.0001 | =0.7457 | =0.7789 | =0.7373 |
| Subgroup . | n . | Gender (M:F) . | Age (Years) . | 2021 WHO Grade (2:3:4) . | CDKN2A (Homozygous Deletion:Retained)* . | MGMT Promoter (Methylated: Unmethylated)* . | Tumor Mutation Burden (Mutations/Mb) . | CNV (%) . | Median PFS (Months) . | Median OS (Months) . |
|---|---|---|---|---|---|---|---|---|---|---|
| IDH-mutant astrocytoma | ||||||||||
| MMR-mutant | 18 | 10:8 | 35.1 ± 2.9 | 1:3:14 | 9:8 | 8:6 | 84.9 ± 13.0 | 21.3 ± 3.2 | 62.1 | 78.5 |
| MMR-wild type | 361 | 234:127 | 35.2 ± 0.5 | 155:118:88 | 67:294 | 93:60 | 15.1 ± 0.9 | 17.3 ± 0.7 | 97.8 | 161.0 |
| P-value | - | =0.4548 | =0.9658 | <0.0001 | =0.0021 | =0.7829 | <0.0001 | =0.1381 | =0.0528 | =0.0069 |
| IDH-wild-type glioblastoma | ||||||||||
| MMR-mutant | 20 | 9:11 | 51.7 ± 3.0 | 0:0:20 | 9:11 | 9:8 | 131.9 ± 14.8 | 20.6 ± 2.7 | 6.0 | 27.2 |
| MMR-wild type | 906 | 554:352 | 54.9 ± 0.5 | 0:0:906 | 256:261 | 158:343 | 13.6 ± 0.6 | 18.8 ± 0.3 | 10.0 | 22.0 |
| P-value | - | =0.1670 | =0.3707 | - | =0.8207 | =0.0702 | <0.0001 | =0.7457 | =0.7789 | =0.7373 |
Note: MMR, mismatch repair; CNV, copy number variation; PFS, progression-free survival; OS, overall survival; bold indicates statistical significance to a level of < 0.05;
*not all cases had available CDKN2A deletion or MGMT promoter methylation data.
Clinical and Molecular Features in IDH-Mutant Astrocytomas and IDH-Wild-Type Glioblastomas With and Without MMR Gene Mutations in the Primary Tumor
| Subgroup . | n . | Gender (M:F) . | Age (Years) . | 2021 WHO Grade (2:3:4) . | CDKN2A (Homozygous Deletion:Retained)* . | MGMT Promoter (Methylated: Unmethylated)* . | Tumor Mutation Burden (Mutations/Mb) . | CNV (%) . | Median PFS (Months) . | Median OS (Months) . |
|---|---|---|---|---|---|---|---|---|---|---|
| IDH-mutant astrocytoma | ||||||||||
| MMR-mutant | 18 | 10:8 | 35.1 ± 2.9 | 1:3:14 | 9:8 | 8:6 | 84.9 ± 13.0 | 21.3 ± 3.2 | 62.1 | 78.5 |
| MMR-wild type | 361 | 234:127 | 35.2 ± 0.5 | 155:118:88 | 67:294 | 93:60 | 15.1 ± 0.9 | 17.3 ± 0.7 | 97.8 | 161.0 |
| P-value | - | =0.4548 | =0.9658 | <0.0001 | =0.0021 | =0.7829 | <0.0001 | =0.1381 | =0.0528 | =0.0069 |
| IDH-wild-type glioblastoma | ||||||||||
| MMR-mutant | 20 | 9:11 | 51.7 ± 3.0 | 0:0:20 | 9:11 | 9:8 | 131.9 ± 14.8 | 20.6 ± 2.7 | 6.0 | 27.2 |
| MMR-wild type | 906 | 554:352 | 54.9 ± 0.5 | 0:0:906 | 256:261 | 158:343 | 13.6 ± 0.6 | 18.8 ± 0.3 | 10.0 | 22.0 |
| P-value | - | =0.1670 | =0.3707 | - | =0.8207 | =0.0702 | <0.0001 | =0.7457 | =0.7789 | =0.7373 |
| Subgroup . | n . | Gender (M:F) . | Age (Years) . | 2021 WHO Grade (2:3:4) . | CDKN2A (Homozygous Deletion:Retained)* . | MGMT Promoter (Methylated: Unmethylated)* . | Tumor Mutation Burden (Mutations/Mb) . | CNV (%) . | Median PFS (Months) . | Median OS (Months) . |
|---|---|---|---|---|---|---|---|---|---|---|
| IDH-mutant astrocytoma | ||||||||||
| MMR-mutant | 18 | 10:8 | 35.1 ± 2.9 | 1:3:14 | 9:8 | 8:6 | 84.9 ± 13.0 | 21.3 ± 3.2 | 62.1 | 78.5 |
| MMR-wild type | 361 | 234:127 | 35.2 ± 0.5 | 155:118:88 | 67:294 | 93:60 | 15.1 ± 0.9 | 17.3 ± 0.7 | 97.8 | 161.0 |
| P-value | - | =0.4548 | =0.9658 | <0.0001 | =0.0021 | =0.7829 | <0.0001 | =0.1381 | =0.0528 | =0.0069 |
| IDH-wild-type glioblastoma | ||||||||||
| MMR-mutant | 20 | 9:11 | 51.7 ± 3.0 | 0:0:20 | 9:11 | 9:8 | 131.9 ± 14.8 | 20.6 ± 2.7 | 6.0 | 27.2 |
| MMR-wild type | 906 | 554:352 | 54.9 ± 0.5 | 0:0:906 | 256:261 | 158:343 | 13.6 ± 0.6 | 18.8 ± 0.3 | 10.0 | 22.0 |
| P-value | - | =0.1670 | =0.3707 | - | =0.8207 | =0.0702 | <0.0001 | =0.7457 | =0.7789 | =0.7373 |
Note: MMR, mismatch repair; CNV, copy number variation; PFS, progression-free survival; OS, overall survival; bold indicates statistical significance to a level of < 0.05;
*not all cases had available CDKN2A deletion or MGMT promoter methylation data.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
